Literature DB >> 11910314

Attenuation of aortic banding-induced cardiac hypertrophy by propranolol is independent of beta-adrenoceptor blockade.

Giuseppe Marano1, Sergio Palazzesi, Antonello Fadda, Alessandro Vergari, Alberto U Ferrari.   

Abstract

OBJECTIVE: Racemic propranolol attenuates cardiac hypertrophy secondary to abdominal aortic banding-induced pressure overload by a mechanism independent of its effect on cardiac work load. This was only observed, however, using doses of propranolol that were much higher than those needed to induce beta-adrenoceptor blockade. Thus, the question remains as to whether the antihypertrophic effect of propranolol depends on its ability to antagonize cardiac beta-adrenoceptor-mediated action (positive chronotropic effect, trophic effect) or on beta-adrenoceptor-independent action.
METHODS: In a rat model of chronic pressure overload induced by abdominal aortic banding, we evaluated the effects on left ventricular hypertrophy (LVH) of the propranolol isomers, L-propranolol and D-propranolol, which compared to L-isomer is approximately 50-fold less potent as a beta-adrenoceptor antagonist, but is similarly potent as a membrane-stabilizer, as well as of timolol, a non-selective beta-adrenergic antagonist devoid of membrane stabilizing activity, and disopyramide, which is a membrane stabilizer, but not a beta-adrenoceptor blocker.
RESULTS: Compared to sham-operated rats, banded rats had 30% greater left ventricular to body weight (LVW/BW) ratio (P < 0.01). The increase in LVW/BW ratio was significantly attenuated by treatment with 40 and 80 (but not 10) mg/kg per day of L-propranolol. Left ventricular hypertrophy was also prevented by D-propranolol, 40 and 80 mg/kg per day, and disopyramide, 50 mg/kg per day, whereas timolol, 30 and 60 mg/kg per day, showed no antihypertrophic effect. In separate groups of banded rats in which the reduction in heart rate induced by propranolol (80 mg/kg per day) was prevented by chronic cardiac pacing at 375 b.p.m., hypertrophy was again prevented, indicating that the effects of L-propranolol on LVH are not related to a reduction in cardiac work load.
CONCLUSIONS: In the aortic banding-induced model of LVH: (i) the antihypertrophic effect of propranolol is independent of its beta-adrenergic blocking activity; and Iii) since disopyramide and D-propranolol also proved to be able to antagonize banding-induced LVH, the hypothesis is proposed that membrane-stabilizing activity, among the ancillary properties of propranolol, most likely accounts for the antihypertrophic effect of this drug.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11910314     DOI: 10.1097/00004872-200204000-00036

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  9 in total

1.  Propranolol enhances cell cycle-related gene expression in pressure overloaded hearts.

Authors:  Marco Musumeci; Sonia Maccari; Paola Sestili; Michele Signore; Paola Molinari; Caterina Ambrosio; Tonino Stati; William H Colledge; Andrew A Grace; Liviana Catalano; Giuseppe Marano
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

2.  Inhibition of left ventricular remodelling preserves chamber systolic function in pressure-overloaded mice.

Authors:  Giuseppe Marano; Sergio Palazzesi; Alessandro Vergari; Liviana Catalano; Simona Gaudi; Claudia Testa; Rossella Canese; Giulia Carpinelli; Franca Podo; Alberto U Ferrari
Journal:  Pflugers Arch       Date:  2003-04-25       Impact factor: 3.657

3.  Cardiac reactive oxygen species after traumatic brain injury.

Authors:  Brett E Larson; David W Stockwell; Stefan Boas; Trevor Andrews; George C Wellman; Warren Lockette; Kalev Freeman
Journal:  J Surg Res       Date:  2011-10-24       Impact factor: 2.192

4.  Propranolol causes a paradoxical enhancement of cardiomyocyte foetal gene response to hypertrophic stimuli.

Authors:  M Patrizio; M Musumeci; T Stati; P Fasanaro; S Palazzesi; L Catalano; G Marano
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

5.  Na+/H+ exchange inhibition attenuates left ventricular remodeling and preserves systolic function in pressure-overloaded hearts.

Authors:  Giuseppe Marano; Alessandro Vergari; Liviana Catalano; Simona Gaudi; Sergio Palazzesi; Marco Musumeci; Tonino Stati; Alberto U Ferrari
Journal:  Br J Pharmacol       Date:  2004-01-12       Impact factor: 8.739

6.  Knockout of beta(1)- and beta(2)-adrenoceptors attenuates pressure overload-induced cardiac hypertrophy and fibrosis.

Authors:  H Kiriazis; K Wang; Q Xu; X-M Gao; Z Ming; Y Su; X-L Moore; G Lambert; M E Gibbs; A M Dart; X-J Du
Journal:  Br J Pharmacol       Date:  2008-01-14       Impact factor: 8.739

7.  β-AR blockers suppresses ER stress in cardiac hypertrophy and heart failure.

Authors:  Li Ni; Changqing Zhou; Quanlu Duan; Jiagao Lv; Xiangning Fu; Yong Xia; Dao Wen Wang
Journal:  PLoS One       Date:  2011-11-02       Impact factor: 3.240

8.  Celecoxib prevents pressure overload-induced cardiac hypertrophy and dysfunction by inhibiting inflammation, apoptosis and oxidative stress.

Authors:  Chi Zhang; Fan Wang; Yingxia Zhang; Yimin Kang; Haisheng Wang; Mingming Si; Liping Su; Xue Xin; Feng Xue; Fei Hao; Lechu Yu; Jinzhong Xu; Yanlong Liu; Mingming Xue
Journal:  J Cell Mol Med       Date:  2015-10-29       Impact factor: 5.310

9.  Role of connexins in infantile hemangiomas.

Authors:  Katja Blanke; Ingo Dähnert; Aida Salameh
Journal:  Front Pharmacol       Date:  2013-04-16       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.